120 related articles for article (PubMed ID: 38643887)
1. Correlations among serum alpha-(1,6)-fucosyltransferase and early symptoms associated with Parkinson's disease: A cross-sectional retrospective study.
Wang QR; Yu X; Li Y; Zhu MZ
Brain Res Bull; 2024 Jun; 212():110959. PubMed ID: 38643887
[TBL] [Abstract][Full Text] [Related]
2. Associations of sleep disorders with serum neurofilament light chain levels in Parkinson's disease.
Qi WY; Sun Y; Guo Y; Tan L
BMC Neurol; 2024 May; 24(1):147. PubMed ID: 38693483
[TBL] [Abstract][Full Text] [Related]
3. The association of serum neurofilament light chains with early symptoms related to Parkinson's disease: A cross-sectional study.
Wang X; Yang X; He W; Song X; Zhang G; Niu P; Chen T
J Affect Disord; 2023 Dec; 343():144-152. PubMed ID: 37805158
[TBL] [Abstract][Full Text] [Related]
4. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
5. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
[TBL] [Abstract][Full Text] [Related]
6. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
Ye R; Locascio JJ; Goodheart AE; Quan M; Zhang B; Gomperts SN
Parkinsonism Relat Disord; 2021 Apr; 85():11-16. PubMed ID: 33639572
[TBL] [Abstract][Full Text] [Related]
7. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease.
Chen CH; Lee BC; Lin CH
J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease.
Urso D; Batzu L; Logroscino G; Ray Chaudhuri K; Pereira JB
Neurobiol Dis; 2023 Sep; 185():106237. PubMed ID: 37499883
[TBL] [Abstract][Full Text] [Related]
9. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD).
Niemann L; Lezius S; Maceski A; Leppert D; Englisch C; Schwedhelm E; Zeller T; Gerloff C; Kuhle J; Choe CU
Parkinsonism Relat Disord; 2021 Sep; 90():44-48. PubMed ID: 34352610
[TBL] [Abstract][Full Text] [Related]
10. Association between serum neurofilament light chain levels and sleep disorders in patients with Parkinson's disease.
Li Y; Li F; Liu X; Zu J; Zhang W; Zhou S; Zhu J; Zhang T; Cui G; Xu C
Neurosci Lett; 2023 Aug; 812():137394. PubMed ID: 37437874
[TBL] [Abstract][Full Text] [Related]
11. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.
Oosterveld LP; Verberk IMW; Majbour NK; El-Agnaf OM; Weinstein HC; Berendse HW; Teunissen CE; van de Berg WDJ
Mov Disord; 2020 Feb; 35(2):288-295. PubMed ID: 31737952
[TBL] [Abstract][Full Text] [Related]
12. Plasma NfL, clinical subtypes and motor progression in Parkinson's disease.
Pilotto A; Imarisio A; Conforti F; Scalvini A; Masciocchi S; Nocivelli S; Turrone R; Gipponi S; Cottini E; Borroni B; Rizzetti MC; Pizzi M; Bonanni L; Sturchio A; Espay AJ; Zetterberg H; Ashton NJ; Hye A; Padovani A
Parkinsonism Relat Disord; 2021 Jun; 87():41-47. PubMed ID: 33964785
[TBL] [Abstract][Full Text] [Related]
13. Serum level of YWHAG as a diagnostic marker of cognitive impairment in Parkinson's disease patients.
Peng Y; Zhu L; Bai Q; Wang L; Li Q
Acta Neurol Belg; 2024 Jun; 124(3):879-885. PubMed ID: 38286872
[TBL] [Abstract][Full Text] [Related]
14. The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease.
Teng X; Mao S; Wu H; Shao Q; Zu J; Zhang W; Zhou S; Zhang T; Zhu J; Cui G; Xu C
J Neurochem; 2023 Apr; 165(2):268-276. PubMed ID: 36776136
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.
Hu X; Yang Y; Gong D
Neurol Sci; 2017 Mar; 38(3):407-414. PubMed ID: 27896490
[TBL] [Abstract][Full Text] [Related]
16. Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease.
Zhu Y; Yang B; Wang F; Liu B; Li K; Yin K; Yin WF; Zhou C; Tian S; Ren H; Pang A; Yang X
J Neuroimmunol; 2021 Sep; 358():577662. PubMed ID: 34311152
[TBL] [Abstract][Full Text] [Related]
17. Increased plasma orexin-A concentrations are associated with the non-motor symptoms in Parkinson's disease patients.
Huang S; Zhao Z; Ma J; Hu S; Li L; Wang Z; Sun W; Shi X; Li M; Zheng J
Neurosci Lett; 2021 Jan; 741():135480. PubMed ID: 33161104
[TBL] [Abstract][Full Text] [Related]
18. Increased Serum Cystatin C in Early Parkinson's Disease with Objective Sleep Disturbances.
Xiong KP; Dai YP; Chen J; Xu JM; Wang Y; Feng P; You SJ; Liu CF
Chin Med J (Engl); 2018 Apr; 131(8):907-911. PubMed ID: 29664049
[TBL] [Abstract][Full Text] [Related]
19. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
Hansson O; Janelidze S; Hall S; Magdalinou N; Lees AJ; Andreasson U; Norgren N; Linder J; Forsgren L; Constantinescu R; Zetterberg H; Blennow K;
Neurology; 2017 Mar; 88(10):930-937. PubMed ID: 28179466
[TBL] [Abstract][Full Text] [Related]
20. Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
Lin CH; Li CH; Yang KC; Lin FJ; Wu CC; Chieh JJ; Chiu MJ
Neurology; 2019 Sep; 93(11):e1104-e1111. PubMed ID: 31420461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
